Slide 1: Sustainability Day
Sustainability Day March 24, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable. Actual performance and other results may differ significantly due to various factors. Such facto
Slide 3: Agenda
Agenda Toward Sustainable Growth（14:00-14:20） Representative Director, President and Chief Operating Officer Toichi Takino Initiative to Foster a Sense of Group Unity for Sustainable Growth（14:20-14:35） Representative Director, Executive Vice President / Executive Director / Corporate Strategy & Pla
Slide 4: Toward Sustainable Growth
Toward Sustainable Growth 3 / 29
Slide 5: Three Pillars of Sustainable Growth
Three Pillars of Sustainable Growth 売上高 Life Cycle Management of OPDIVO Strengthening the Pipeline • Loss of Exclusivity － US: 2028 • Tirabrutinib / ONO-4059 (Filed) － EU: 2030 Sales Revenue • Sapablursen / ONO-0530 (Phase 2) P － JP : 2031 Including OPDIVO 120 JPY bn • ONO-4578 (Phase 2) P • ONO-280
Slide 6: Life Cycle Management of OPDIVO: Strategic LCM Initiatives in Progress
Life Cycle Management of OPDIVO : Strategic LCM Initiatives in Progress OPDIVO Sales in JP (JPY bn) Approved Indications Melanoma 2014 Price Revision 142.3 145.5 NSCLC 2015 (Forecast) RCC 2016 120.3 120.0 Others 112.4 Hodgkin’s lymphoma 2016 103.9 GC 98.8 90.1 90.6 87.3 Head and Neck Cancer 2017 UC
Slide 7: Launch Projections (- 2031)
Launch Projections (- 2031) US & EU Multiple System Atrophy Sustaining Global Pipeline Momentum Toward Continuous Launches ONO-2808 Gastric Cancer GIST 4L TGCT PCNSL KIT Exon 11+17/18 ONO-4578 GIST 2L QINLOCK ROMVIMZA Tirabrutinib （ONO-4059） QINLOCK Polycythemia Vera Sapablursen （ONO-0530） 2024 2025
Slide 8: Evolution of the Collaboration with Deciphera
Evolution of the Collaboration with Deciphera Past Current Prioritize QINLOCK/ROMVIMZA growth One-team collaboration focused on global and launch through collaboration development of new projects Shift from standalone to group-wide collaboration Faster and more Efficient Ono Group execution 7 / 29
Slide 9: Prospect for the Next 10 Years Growth Drivers
Prospect for the Next 10 Years Growth Drivers Global QINLOCK (GIST) ROMVIMZA (TGCT) Tirabrutinib (PCNSL) Global sales Sapablursen (Polycythemia Vera) Japan sales ONO-4578 (Gastric Cancer) (other than OPDIVO) ONO-2808 (MSA) etc. Japan Povetacicept Royalties Cenobamate, Gel-One® etc. Japan sales Nivol
Slide 10: External evaluation of ESG in FY 2025
External evaluation of ESG in FY 2025 Rating Agency Evaluation Content Number of Selections Both Climate Change and Water Security A-list in the climate change Efforts A（Double A）: 5 consecutive years CDP Climate Change : 8 consecutive years A-list in the water security efforts Water Security effort
Slide 11: Initiative to Foster a Sense of Group Unity for Sustainable Growth
Initiative to Foster a Sense of Group Unity for Sustainable Growth 10 / 29
Slide 12: Evolution of the Collaboration with Deciphera
Evolution of the Collaboration with Deciphera Past Current Prioritize QINLOCK/ROMVIMZA growth One-team collaboration focused on global and launch through collaboration development of new projects Shift from standalone to group-wide collaboration Faster and more Efficient Ono Group execution 11 / 29
Slide 13: Mission Statement of Both Ono Pharma and Deciphera
Mission Statement of Both Ono Pharma and Deciphera There are things that Ono Group has valued, and there are things that Deciphera has valued. By learning about and connecting with each other’s values, we can achieve mutual understanding 相互理解 Ono Group Deciphera Philosophy Mutual One Mission, Inspir
Slide 14: History of Ono Pharmaceutical (FY2017 - )
History of Ono Pharmaceutical (FY2017 - ) FY2017 - FY2031 Implementation of the Medium-Term Management Plan for 5 years×3 terms 600 ROMVIMZA Deciphera joined Ono group (June 2024) US & EU: Launched FY2023 Sales revenue: 500 JPY bn (JPY bn) 400 Anti-PD-1 antibody Opdivo launched (2014) Toward Further
Slide 15: Ono's Mission Statement
Ono’s Mission Statement PHILOSOPHY Dedicated to the Fight against Disease and Pain (Established in 1968) VISION (Established in 2014) Be Passionate Challengers Ono aims to be a world-changing team VALUE The greater the challenge, the more passionately Ono will (Established in 2014) rise to meet
Slide 16: For Dissemination of the Mission Statement
For Dissemination of the Mission Statement ■Understanding the background and significance of the Mission Statement What I expect from our employees Actions that I expect our employees to take based on the Mission Statement Toichi Takino Gyo Sagara Representative Director, Representative Director, Pr
Slide 17: Deciphera's PATHS Values are the Foundation for How We Work
Deciphera’s PATHS Values are the Foundation for How We Work PATIENTS We are committed to improving the lives of patients living with cancer. They are the driving force behind everything we do. ACCOUNTABILITY We demand accountability for our actions, behaviors, and performance. We recognize our duty
Slide 18: Role and Responsibilities
Role and Responsibilities PURPOSE ROLE RESPONSIBILITIES Thoughtfully reflect on progress, goals and Performance Management at achievements Your role is to share your Deciphera is a holistic, perspective on progress made continuous process that aligns against “what” you completed individual and team
Slide 19: History of Ono Pharmaceutical (FY2017 - )
History of Ono Pharmaceutical (FY2017 - ) FY2017 - FY2031 Implementation of the Medium-Term Management Plan for 5 years×3 terms 600 ROMVIMZA Deciphera joined ONO group (June 2024) US & EU: Launched FY2023 Sales revenue: 500 JPY bn (JPY bn) 400 Anti-PD-1 antibody Opdivo launched (2014) Toward Further
Slide 20: Medium-Term Management Plan: Growth Strategies for Going Global
Medium-Term Management Plan: Growth Strategies for Going Global Challenges to Transform Business Models Contributions Attain the position of a global to People’s specialty pharma and create Health new value We are expanding our presence around the world by taking advantage of powerful R&D We have ac
Slide 21: Medium-Term Management Plan: Growth Strategies for Going Global
Medium-Term Management Plan: Growth Strategies for Going Global 2nd Medium-Term Management Plan Contributions （2022-2026） Attain the position of a global to People’s specialty pharma and create Health new value We are expanding our presence around the world by taking advantage of powerful R&D We hav
Slide 22: Global Initiatives to Foster a Sense of Unity
Global Initiatives to Foster a Sense of Unity • ONO management visits Deciphera, ONO PHARMA KOREA and ONO PHARMA TAIWAN and has regularly dialogue based on Ono’s Mission. • Held Deciphera’s All Company Event • Conducted training sessions aiming to disseminate the Mission Statement at ONO PHARMA KORE
Slide 23: Group-Wide Initiative to Foster a Sense of Unity: All-Division Meeting and CEO Award
Group-Wide Initiative to Foster a Sense of Unity｜All-Division Meeting and CEO Award All-Division Meeting CEO Award The All-Division Meeting includes employees in Japan, along with participation from the management of Employees from Deciphera, Ono Deciphera, Ono Pharma Korea, and Ono Pharma Taiwan. P
Slide 24: Initiatives in Japan to Foster a Sense of Unity: Dialogue Initiatives by Each Division Head
Initiatives in Japan to Foster a Sense of Unity｜Dialogue Initiatives by Each Division Head • Engagement score for FY2025 was 72, up 2pt from the previous year. • The score increased in multiple categories and questions, notably with a significant improvement in questions related to “dialogue with co
Slide 25: Trend of Engagement Survey Results
Trend of Engagement Survey Results • Engagement scores have been increasing every year, narrowing the difference from the Global Life Science Benchmark (BM) score over the years from -11pt in FY2022 to -4pt in FY2025（Engagement score: 72, N=3,742） • In FY2025, Deciphea participated in this survey fo
Slide 26: Acquisition of Deciphera from the Perspective of an Independent Outside Director
Acquisition of Deciphera from the Perspective of an Independent Outside Director 25 / 29
Slide 27: Management
Management Name Positions, Responsibilities and important concurrent holding of positions Gyo Sagara Representative Director, Chairman of the Board and Chief Executive Officer Internal Toichi Takino Representative Director, President and Chief Operating Officer (3) Representative Director, Executive
Slide 28: Board Deliberations Prior to the Acquisition
Board Deliberations Prior to the Acquisition ・Alignment with the Company’s mid-term strategy Review and (promotion of global expansion) Assessment ・Expected synergies ・Appropriateness of enterprise value assessment ・Securing and retaining key human resources ・Consideration for the acquired company (
Slide 29: Oversight of Post-Merger Integration (PMI)
Oversight of Post-Merger Integration (PMI) • Composition of the Board of Directors (dispatch of a CEO from Ono Pharma) • Decision-making authority (to be reviewed on an ongoing basis Governance while fostering mutual understanding) • Integration of European and US operations (promotion of globalizat
Slide 30: Evaluation of the Acquisition and PMI
Evaluation of the Acquisition and PMI • Deciphera’s business performance is progressing steadily • The development pipeline (including ROMVIMZA) is progressing smoothly as originally planned, and three development candidates (ONO-4578, ONO-2808, and sapablursen) are expected to transition smoothly t
Slide 31: Dedicated to the Fight against Disease and Pain
Dedicated to the Fight against Disease and Pain